Evicenter
P&T meetings

Dersimelagon (MT-7117)

Erythropoietic protoporphyria or X-linked protoporphyria

Manufacturer
LEO Pharma
Regulatory submission
NDA submitted June 2026
Last updated
100 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Phototherapy and sunlight hardening

1 evidence topic · 1 source

Guideline position on narrowband ultraviolet B phototherapy

“For patients without access to afamelanotide, limited natural sunlight exposure or low-dose hardening phototherapy with narrowband UVB increased slowly over time to induce a gradual increase in endogenous melanin production may be considered for prevention of phototoxic symptoms” (opens the source at this quote in a new tab)

“However the effectiveness of this therapy is unclear and not well established” (opens the source at this quote in a new tab)

“For patients who are sensitive to indoor lighting, utilizing indoor lights that minimize the amount of blue light may be considered” (opens the source at this quote in a new tab)